GlassScriptPhysician profile
Abraham Chachoua
NPI 1518968643
$78,921.89
in general payments reported to CMS, 2019-2025
10 companies · $76K in 2025
The $76K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,800 · 2020: $20.87 · 2021: $38.69 · 2022: $14.54 · 2023: $27.70 · 2024: $22.83 · 2025: $76K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $71K · Travel and Lodging: $3,760 · Food and Beverage: $993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $71,295.00 |
| Travel and Lodging | $3,759.77 |
| Food and Beverage | $993.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galvanize Therapeutics, INC | $73,635.45 | 2025 | Aliya System |
| Astrazeneca Pharmaceuticals LP | $2,933.57 | 2019-2025 | Tagrisso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,995.00 | 2025 | |
| Tempus Ai, INC | $206.14 | 2024-2025 | Xt Cdx |
| E.R. Squibb & Sons, L.L.C. | $53.23 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $29.52 | 2025 | Keytruda Qlex, Keytruda |
| Foundation Medicine, INC. | $27.70 | 2023 | |
| Amgen INC. | $20.87 | 2020 | |
| Novocure INC. | $20.41 | 2025 | Optune Lua (Novottf-200t) |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Chachoua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.